Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDVJKW)

Drug Name

TAK-637 Drug Info

Synonyms

TAK-637; UNII-QRT7W0TL6X; QRT7W0TL6X; CHEMBL339486; SCHEMBL122948; TAK637; GTPL9329; TAK 637; BDBM50081420; compound (aR,9R)-8b [PMID: 10508446]; 7H-(1,4)Diazocino(2,1-g)(1,7)naphthyridine-6,13-dione, 7-((3,5-bis(trifluoromethyl)phenyl)methyl)-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-, (9R)-; (Ar,9R)-7-(3,5-bis(trifluoromethyl)benzyl)-8,9,10,11-tetrahydro-9-methyl-5-(4-methylphenyl)-7H-(1,4)diazocino(2,1-g)(1,7)naphthyridine-6,13-dione

Indication

Disease Entry	ICD 11	Status	REF
Depression	6A70-6A7Z	Discontinued in Phase 2	[1]

Cross-matching ID

PubChem CID: 9894349
CAS Number: CAS 183549-93-1
TTD Drug ID: DMDVJKW

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Substance-P receptor (TACR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aprepitant	DM053KT	Depression	6A70-6A7Z	Approved	[2]
Selegiline	DM6034S	Major depressive disorder	6A70.3	Approved	[3]
Rolapitant	DM8XP26	Chemotherapy-induced nausea	MD90	Approved	[4]
Netupitant	DMEKAYI	Chemotherapy-induced nausea	MD90	Phase 3	[4]
Serlopitant	DM5VH6U	Prurigo nodularis	EC91.0	Phase 3	[5]
LY-686017	DM7WORZ	Atopic dermatitis	EA80	Phase 3	[6]
Elinzanetant	DMC6EFI	Hot flushes	GA30	Phase 3	[7]
CP-122721	DMSWLM5	Major depressive disorder	6A70.3	Phase 2	[8]
FR139317	DMEL5SV	Hypertension	BA00-BA04	Phase 2	[3]
VOFOPITANT HYDROCHLORIDE	DMQMYP5	Vomiting	MD90	Phase 2	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Substance-P receptor (TACR1)	TTZPO1L	NK1R_HUMAN	Antagonist	[1]

------------------------------------------------------------------------------------

References

1	Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
2	Potent, brain-penetrant, hydroisoindoline-based human neurokinin-1 receptor antagonists. J Med Chem. 2009 May 14;52(9):3039-46.
3	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
4	Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells. Exp Brain Res. 2014 Aug;232(8):2637-44.
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Stress-related neuropeptides and alcoholism: CRH, NPY and beyond. Alcohol. 2009 November; 43(7): 491-498.
7	Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women. J Clin Endocrinol Metab. 2021 Jul 13;106(8):e3221-e3234.
8	A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006 Dec;7(17):2355-68.
9	Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenicchemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jun;10(6):549-58.